756 related articles for article (PubMed ID: 7685907)
1. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase.
Tisdale M; Kemp SD; Parry NR; Larder BA
Proc Natl Acad Sci U S A; 1993 Jun; 90(12):5653-6. PubMed ID: 7685907
[TBL] [Abstract][Full Text] [Related]
2. Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(+/-)-2'-deoxy-3'-oxa-4'-thiocytidine, dOTC].
Taylor DL; Ahmed PS; Tyms AS; Wood LJ; Kelly LA; Chambers P; Clarke J; Bedard J; Bowlin TL; Rando RF
Antivir Chem Chemother; 2000 Jul; 11(4):291-301. PubMed ID: 10950391
[TBL] [Abstract][Full Text] [Related]
3. Identification of a mutation at codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2',3'-dideoxycytidine and 2',3'-dideoxy-3'-thiacytidine.
Gu Z; Gao Q; Fang H; Salomon H; Parniak MA; Goldberg E; Cameron J; Wainberg MA
Antimicrob Agents Chemother; 1994 Feb; 38(2):275-81. PubMed ID: 7514855
[TBL] [Abstract][Full Text] [Related]
4. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy.
Larder BA; Kemp SD; Harrigan PR
Science; 1995 Aug; 269(5224):696-9. PubMed ID: 7542804
[TBL] [Abstract][Full Text] [Related]
5. High-level resistance to (-) enantiomeric 2'-deoxy-3'-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase.
Boucher CA; Cammack N; Schipper P; Schuurman R; Rouse P; Wainberg MA; Cameron JM
Antimicrob Agents Chemother; 1993 Oct; 37(10):2231-4. PubMed ID: 7504909
[TBL] [Abstract][Full Text] [Related]
6. Infectious amplification of wild-type human immunodeficiency virus from patients' lymphocytes and modulation by reverse transcriptase inhibitors in vitro.
Mathez D; Schinazi RF; Liotta DC; Leibowitch J
Antimicrob Agents Chemother; 1993 Oct; 37(10):2206-11. PubMed ID: 7504908
[TBL] [Abstract][Full Text] [Related]
7. A novel Met-to-Thr mutation in the YMDD motif of reverse transcriptase from feline immunodeficiency virus confers resistance to oxathiolane nucleosides.
Smith RA; Remington KM; Lloyd RM; Schinazi RF; North TW
J Virol; 1997 Mar; 71(3):2357-62. PubMed ID: 9032372
[TBL] [Abstract][Full Text] [Related]
8. Retention of marked sensitivity to (S)-4-isopropoxycarbonyl-6-methoxy-3-(methylthiomethyl)-3,4-di hydroquin oxaline-2(1H)-thione (HBY 097) by an azidothymidine (AZT)-resistant human immunodeficiency virus type 1 (HIV-1) strain subcultured in the combined presence of quinoxaline HBY 097 and 2',3'-dideoxy-3'-thiacytidine (lamivudine).
Balzarini J; Pelemans H; Riess G; Roesner M; Winkler I; De Clercq E; Kleim JP
Biochem Pharmacol; 1998 Mar; 55(5):617-25. PubMed ID: 9515572
[TBL] [Abstract][Full Text] [Related]
9. Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene that encodes cross-resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine.
Gu Z; Gao Q; Li X; Parniak MA; Wainberg MA
J Virol; 1992 Dec; 66(12):7128-35. PubMed ID: 1279198
[TBL] [Abstract][Full Text] [Related]
10. 3'-Azido-3'-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors.
Larder BA
Antimicrob Agents Chemother; 1992 Dec; 36(12):2664-9. PubMed ID: 1282792
[TBL] [Abstract][Full Text] [Related]
11. Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides.
Schinazi RF; Lloyd RM; Nguyen MH; Cannon DL; McMillan A; Ilksoy N; Chu CK; Liotta DC; Bazmi HZ; Mellors JW
Antimicrob Agents Chemother; 1993 Apr; 37(4):875-81. PubMed ID: 7684216
[TBL] [Abstract][Full Text] [Related]
12. Convergent combination therapy can select viable multidrug-resistant HIV-1 in vitro.
Larder BA; Kellam P; Kemp SD
Nature; 1993 Sep; 365(6445):451-3. PubMed ID: 7692302
[TBL] [Abstract][Full Text] [Related]
13. Human immunodeficiency virus type 1 drug susceptibility during zidovudine (AZT) monotherapy compared with AZT plus 2',3'-dideoxyinosine or AZT plus 2',3'-dideoxycytidine combination therapy. The protocol 34,225-02 Collaborative Group.
Larder BA; Kohli A; Bloor S; Kemp SD; Harrigan PR; Schooley RT; Lange JM; Pennington KN; St Clair MH
J Virol; 1996 Sep; 70(9):5922-9. PubMed ID: 8709213
[TBL] [Abstract][Full Text] [Related]
14. Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme.
Back NK; Nijhuis M; Keulen W; Boucher CA; Oude Essink BO; van Kuilenburg AB; van Gennip AH; Berkhout B
EMBO J; 1996 Aug; 15(15):4040-9. PubMed ID: 8670908
[TBL] [Abstract][Full Text] [Related]
15. Genotypic and phenotypic characterization of HIV-1 isolated from patients receiving (--)-2',3'-dideoxy-3'-thiacytidine.
Kavlick MF; Shirasaka T; Kojima E; Pluda JM; Hui F; Yarchoan R; Mitsuya H
Antiviral Res; 1995 Oct; 28(2):133-46. PubMed ID: 8585767
[TBL] [Abstract][Full Text] [Related]
16. Natural occurrence of drug resistance mutations in the reverse transcriptase of human immunodeficiency virus type 1 isolates.
Nájera I; Richman DD; Olivares I; Rojas JM; Peinado MA; Perucho M; Nájera R; López-Galíndez C
AIDS Res Hum Retroviruses; 1994 Nov; 10(11):1479-88. PubMed ID: 7534096
[TBL] [Abstract][Full Text] [Related]
17. Significance of amino acid variation at human immunodeficiency virus type 1 reverse transcriptase residue 210 for zidovudine susceptibility.
Harrigan PR; Kinghorn I; Bloor S; Kemp SD; Nájera I; Kohli A; Larder BA
J Virol; 1996 Sep; 70(9):5930-4. PubMed ID: 8709214
[TBL] [Abstract][Full Text] [Related]
18. A novel point mutation at position 156 of reverse transcriptase from feline immunodeficiency virus confers resistance to the combination of (-)-beta-2',3'-dideoxy-3'-thiacytidine and 3'-azido-3'-deoxythymidine.
Smith RA; Remington KM; Preston BD; Schinazi RF; North TW
J Virol; 1998 Mar; 72(3):2335-40. PubMed ID: 9499094
[TBL] [Abstract][Full Text] [Related]
19. Recognition of the highly conserved YMDD region in the human immunodeficiency virus type 1 reverse transcriptase by HLA-A2-restricted cytotoxic T lymphocytes from an asymptomatic long-term nonprogressor.
Harrer E; Harrer T; Barbosa P; Feinberg M; Johnson RP; Buchbinder S; Walker BD
J Infect Dis; 1996 Feb; 173(2):476-9. PubMed ID: 8568316
[TBL] [Abstract][Full Text] [Related]
20. Site-specific incorporation of nucleoside analogs by HIV-1 reverse transcriptase and the template grip mutant P157S. Template interactions influence substrate recognition at the polymerase active site.
Klarmann GJ; Smith RA; Schinazi RF; North TW; Preston BD
J Biol Chem; 2000 Jan; 275(1):359-66. PubMed ID: 10617626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
